Abstract
Objectives: This study included a cohort of advanced renal cell carcinoma patients treated with sunitinib. Since resistance to sunitinib may be mediated through angiogenic cytokines other than VEGF, we measured the circulating levels of three pro-angiogenic cytokines: basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and interleukin (IL)-6. Methods: Cytokines were measured at baseline and on the first day of each treatment cycle until progression in 85 advanced kidney cancer patients treated with sunitinib using a quantitative sandwich enzyme immunoassay (ELISA) technique. Results: Even though no statistically significant differences in the titers of the three cytokines were observed between baseline and the time of progression in the whole patient cohort, in 45.3, 46.6, and 37.3% of the patients a more than 50% increase between baseline and the time of progression was shown in circulating IL-6, bFGF, and HGF, respectively. Furthermore, this increase was more than 100% in 37.3, 44, and 30.6% of the patients, respectively. We also demonstrated that, in these patients, cytokines tended to increase and to remain high immediately before progression. Conclusions: In a large percentage of kidney cancer patients, progression is preceded by a significant increase in pro-angiogenic cytokines other than VEGF.
| Original language | English |
|---|---|
| Pages (from-to) | 115-122 |
| Number of pages | 8 |
| Journal | Oncology |
| Volume | 84 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Dec 2012 |
Fingerprint
Keywords
- Basic fibroblast growth factor
- Hepatocyte growth factor
- Interleukin-6
- Kidney cancer
- Progression
- Sunitinib
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. / Porta, Camillo; Paglino, Chiara; Imarisio, Ilaria; Ganini, Carlo; Sacchi, Lucia; Quaglini, Silvana; Giunta, Vania; De Amici, Mara.
In: Oncology, Vol. 84, No. 2, 12.2012, p. 115-122.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients
AU - Porta, Camillo
AU - Paglino, Chiara
AU - Imarisio, Ilaria
AU - Ganini, Carlo
AU - Sacchi, Lucia
AU - Quaglini, Silvana
AU - Giunta, Vania
AU - De Amici, Mara
PY - 2012/12
Y1 - 2012/12
N2 - Objectives: This study included a cohort of advanced renal cell carcinoma patients treated with sunitinib. Since resistance to sunitinib may be mediated through angiogenic cytokines other than VEGF, we measured the circulating levels of three pro-angiogenic cytokines: basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and interleukin (IL)-6. Methods: Cytokines were measured at baseline and on the first day of each treatment cycle until progression in 85 advanced kidney cancer patients treated with sunitinib using a quantitative sandwich enzyme immunoassay (ELISA) technique. Results: Even though no statistically significant differences in the titers of the three cytokines were observed between baseline and the time of progression in the whole patient cohort, in 45.3, 46.6, and 37.3% of the patients a more than 50% increase between baseline and the time of progression was shown in circulating IL-6, bFGF, and HGF, respectively. Furthermore, this increase was more than 100% in 37.3, 44, and 30.6% of the patients, respectively. We also demonstrated that, in these patients, cytokines tended to increase and to remain high immediately before progression. Conclusions: In a large percentage of kidney cancer patients, progression is preceded by a significant increase in pro-angiogenic cytokines other than VEGF.
AB - Objectives: This study included a cohort of advanced renal cell carcinoma patients treated with sunitinib. Since resistance to sunitinib may be mediated through angiogenic cytokines other than VEGF, we measured the circulating levels of three pro-angiogenic cytokines: basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and interleukin (IL)-6. Methods: Cytokines were measured at baseline and on the first day of each treatment cycle until progression in 85 advanced kidney cancer patients treated with sunitinib using a quantitative sandwich enzyme immunoassay (ELISA) technique. Results: Even though no statistically significant differences in the titers of the three cytokines were observed between baseline and the time of progression in the whole patient cohort, in 45.3, 46.6, and 37.3% of the patients a more than 50% increase between baseline and the time of progression was shown in circulating IL-6, bFGF, and HGF, respectively. Furthermore, this increase was more than 100% in 37.3, 44, and 30.6% of the patients, respectively. We also demonstrated that, in these patients, cytokines tended to increase and to remain high immediately before progression. Conclusions: In a large percentage of kidney cancer patients, progression is preceded by a significant increase in pro-angiogenic cytokines other than VEGF.
KW - Basic fibroblast growth factor
KW - Hepatocyte growth factor
KW - Interleukin-6
KW - Kidney cancer
KW - Progression
KW - Sunitinib
UR - http://www.scopus.com/inward/record.url?scp=84868712956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868712956&partnerID=8YFLogxK
U2 - 10.1159/000342099
DO - 10.1159/000342099
M3 - Article
C2 - 23154434
AN - SCOPUS:84868712956
VL - 84
SP - 115
EP - 122
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 2
ER -